 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LAVA Therapeutics (NASDAQ:LVTX  Get Free Report) and Elanco Animal Health (NYSE:ELAN  Get Free Report) are both medical companies, but which is the better investment? We will contrast...

Contrasting LAVA Therapeutics (NASDAQ:LVTX) and Elanco Animal Health (NYSE:ELAN)

LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and...

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

LAVA Therapeutics (NASDAQ:LVTX  Free Report)  Research analysts at Leerink Partnrs dropped their Q3 2023 earnings per share estimates for LAVA Therapeutics in a research report issued...

Q3 2023 EPS Estimates for LAVA Therapeutics Decreased by Leerink Partnrs (NASDAQ:LVTX)

LAVA Therapeutics (NASDAQ:LVTX  Get Free Report) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 37,900 shares, a...

LAVA Therapeutics (NASDAQ:LVTX) Sees Large Decline in Short Interest

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody...

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

LAVA Therapeutics (NASDAQ:LVTX Free Report) Investment analysts at HC Wainwright raised their Q3 2023 EPS estimates for LAVA Therapeutics in a report released on Wednesday, August 23rd. HC Wainwright analyst A. He now expects that the company will earn ($0.41) per share for the quarter, up from ...

LAVA Therapeutics (NASDAQ:LVTX) Expected to Post Q3 2023 Earnings of ($0.41) Per Share

JMP Securities reiterated their market outperform rating on shares of LAVA Therapeutics (NASDAQ:LVTX Free Report) in a research note published on Wednesday morning, Benzinga reports. JMP Securities currently has a $6.00 price objective on the stock. Separately, HC Wainwright reduced their target ...

JMP Securities Reaffirms Market Outperform Rating for LAVA Therapeutics (NASDAQ:LVTX)

LAVA Therapeutics (NASDAQ:LVTX  Free Report)  Equities researchers at HC Wainwright lifted their Q3 2023 earnings per share estimates for shares of LAVA Therapeutics in a report issued...

HC Wainwright Comments on LAVA Therapeutics' Q3 2023 Earnings (NASDAQ:LVTX)

LAVA Therapeutics (NASDAQ:LVTX  Get Free Report)s stock had its market outperform rating reaffirmed by stock analysts at JMP Securities in a research note issued on Wednesday, Benzinga reports. They presently have a $6.00 price objective on the stock. JMP Securities&#8217...

LAVA Therapeutics (NASDAQ:LVTX) Stock Rating Reaffirmed by JMP Securities

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Lava Therapeutics price target lowered to $6 from $9 at H.C. Wainwright

LAVA Therapeutics NV is an immuno-oncology company. It utilizes its proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.

Watchers	628
52-Wk Low	$1.13
52-Wk High	$7.38

Market Cap	$39.7M
Volume (M)	4,122.00
52-Wk High	$7.38
52-Wk Low	$1.13

LVTX LAVA Therapeutics NV

About

Feed

News

Sentiment

Earnings

Fundamentals